Danai Dima, MD

Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.

Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.

Danai Dima, MD, discusses the implications of real-world data derived from the MajesTEC-1 trial in pretreated patients with multiple myeloma.